Strand Life Sciences, a Reliance Industries Limited subsidiary, plans to expand its CancerSpot multi-cancer early detection test to more hospitals. The company also aims to lower the test price from ₹33,000 to approximately ₹10,000 within two years. This strategy follows a four-year study published in the Proceedings of the National Academy of Sciences (PNAS). According to The Hindu BusinessLine, the research analyzed 1,500 samples from 43 local hospitals.
The non-invasive blood test detects cancer by analyzing tumor DNA in the bloodstream. Chief Executive Officer Dr. Ramesh Hariharan stated the test achieved a 1.4 percent false positive rate and 70 percent sensitivity. The study revealed that tumor and immune cell DNA contributions rise together in cancer patients, aiding detection. CancerSpot uses artificial intelligence to identify methylation patterns, distinguishing cancer cells from normal ones. It can identify the tissue of origin, such as the heart or lungs. The test detects 14 cancer types, including lung, stomach, and pancreatic cancers, though brain cancer remains challenging.
Hariharan emphasized that balancing sensitivity with low false positives is crucial to avoid unnecessary invasive procedures. The liquid biopsy market includes global competitors like Guardant Health and Grail, which have US FDA approvals. Hariharan noted these companies will likely price their tests higher in India. He claimed Strand’s data is superior to Guardant’s in some aspects. While Strand operates in the business-to-business space in the US, it targets India, Asia, the Middle East, and Africa for this test.
In a separate development, Strand Life Sciences has partnered with AstraZeneca India. The collaboration aims to introduce Strand’s cancer treatment selection tests to state governments. The initiative is already active in Andhra Pradesh. Hariharan suggested this partnership could eventually expand to broader screening programs. This move positions Strand to compete in a growing diagnostic market while offering a more affordable alternative to international brands.
